Abstract
A literature search was conducted on the effects of sidenafil and the protocols used in heart failure. The phosphodiesterase-5 inhibitor stands out as a new drug in the cardiologic therapeutic arsenal, since the action of inhibiting the various types of phosphodiesterase causes an increase in cAMP and cGMP in white tissues.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
